S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:TELA

TELA Bio (TELA) Stock Price, News & Analysis

$5.61
+0.05 (+0.90%)
(As of 03/27/2024 ET)
Today's Range
$5.45
$5.67
50-Day Range
$5.30
$7.61
52-Week Range
$4.23
$11.65
Volume
61,046 shs
Average Volume
114,732 shs
Market Capitalization
$138.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

TELA Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
149.6% Upside
$14.00 Price Target
Short Interest
Bearish
2.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of TELA Bio in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.50) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.99 out of 5 stars

Medical Sector

465th out of 939 stocks

Surgical & Medical Instruments Industry

53rd out of 96 stocks

TELA stock logo

About TELA Bio Stock (NASDAQ:TELA)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Stock Price History

TELA Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
TELA Bio (NASDAQ:TELA) Rating Reiterated by JMP Securities
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Q4 2023 TELA Bio Inc Earnings Call
Recap: TELA Bio Q4 Earnings
Tela Bio Announces Commercial Launch Of Liquifix Devices In U.S.
TELA Bio is about to announce its earnings — here's what to expect
TELA Jul 2024 10.000 call
TELA Jul 2024 7.500 put
See More Headlines
Receive TELA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TELA
Fax
N/A
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$15.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+149.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-46,660,000.00
Pretax Margin
-79.83%

Debt

Sales & Book Value

Annual Sales
$58.45 million
Book Value
$0.75 per share

Miscellaneous

Free Float
23,093,000
Market Cap
$138.29 million
Optionable
Optionable
Beta
0.97
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Antony Koblish (Age 58)
    Co-founder, President, CEO & Director
    Comp: $967.67k
  • Mr. Roberto E. Cuca J.D. (Age 56)
    CFO & COO
    Comp: $643.37k
  • Mr. Paul Talmo
    Chief Technology Officer
  • Ms. Megan Smeykal (Age 48)
    VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
  • Mr. D. Taylor Ocasio
    General Counsel & Corporate Secretary
  • Ms. Jennifer Lou Armstrong (Age 54)
    Senior Vice President of Human Resources
  • Mr. Gregory A. Firestone
    Chief Business Officer
  • Mr. Michael Leonard
    Senior Vice President of Technical Operations
  • Mr. Peter C. Murphy (Age 51)
    Chief Commercial Officer
    Comp: $542.34k
  • Louisa Smith
    Investor Relations Contact Officer

TELA Stock Analysis - Frequently Asked Questions

Should I buy or sell TELA Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TELA shares.
View TELA analyst ratings
or view top-rated stocks.

What is TELA Bio's stock price target for 2024?

4 brokers have issued 1-year price objectives for TELA Bio's stock. Their TELA share price targets range from $12.00 to $15.00. On average, they predict the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 149.6% from the stock's current price.
View analysts price targets for TELA
or view top-rated stocks among Wall Street analysts.

How have TELA shares performed in 2024?

TELA Bio's stock was trading at $6.62 at the beginning of the year. Since then, TELA shares have decreased by 15.3% and is now trading at $5.61.
View the best growth stocks for 2024 here
.

When is TELA Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TELA earnings forecast
.

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $7.65 million for the quarter, compared to analyst estimates of $7.30 million. TELA Bio had a negative net margin of 79.83% and a negative trailing twelve-month return on equity of 201.62%.

What guidance has TELA Bio issued on next quarter's earnings?

TELA Bio updated its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.0 million-$76.0 million, compared to the consensus revenue estimate of $75.2 million.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO).

When did TELA Bio IPO?

TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are TELA Bio's major shareholders?

TELA Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (10.43%), AIGH Capital Management LLC (5.63%), Nantahala Capital Management LLC (4.48%), Vanguard Group Inc. (4.08%), Vanguard Group Inc. (4.08%) and UBS Group AG (2.81%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2-, Ew Healthcare Partners Fund 2,, Gregory A Firestone, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca.
View institutional ownership trends
.

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TELA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners